undamentalytics Newsletter
Sign in

Thomsen Jillian B.: insider trades

Chief financial officer, Officer at Nektar Therapeutics. No open-market purchases and 24 sales not made under a pre-set plan, reported from August 17, 2016 to February 17, 2023.

What happened after Thomsen Jillian B.’s sales?

After their sales, the shares moved +21.3% against the index over 12 months on average (a negative figure means selling was the right call); 81% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

Trade by trade

MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 0 — — — — — — Not enough years
Purchases, 6 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the trade 0 — — — — — — Not enough years
Sales, 3 months after the report 21 −5.0% −8.4% 71% 7 −0.71 0.51 No reliable evidence
Sales, 12 months after the report 21 +21.3% −59.0% 81% 7 0.46 0.66 No reliable evidence
Sales, 12 months after the trade 21 +19.1% −52.9% 81% 7 0.42 0.69 No reliable evidence

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Nektar Therapeutics NKTR Chief Financial Officer024August 17, 2016February 17, 2023

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
February 17, 2023February 16, 2023 NKTR Sale $30,801 not yetnot yetnot yet
November 18, 2022November 16, 2022 NKTR Sale $39,609 not yetnot yetnot yet
May 17, 2022May 16, 2022 NKTR Sale $23,072 not yetnot yetnot yet
February 18, 2022February 16, 2022 NKTR Sale $25,875 −58.1%−66.1%−65.2%
November 17, 2021November 16, 2021 NKTR Sale $88,712 −3.1%−55.9%−59.1%
August 18, 2021August 16, 2021 NKTR Sale $184,478 −8.5%−62.1%−63.5%
May 19, 2021May 17, 2021 NKTR Sale $245,055 −34.3%−73.5%−76.2%
February 18, 2021February 16, 2021 NKTR Sale $261,841 −34.0%−70.7%−65.0%
November 18, 2020November 16, 2020 NKTR Sale $202,754 +21.7%−64.6%−52.8%
August 19, 2020August 17, 2020 NKTR Sale $26,889 −16.5%−62.1%−63.7%
May 20, 2020May 18, 2020 NKTR Sale $30,771 −31.4%−64.2%−61.7%
February 20, 2020February 18, 2020 NKTR Sale $31,156 +8.2%−23.4%−3.2%
November 20, 2019November 18, 2019 NKTR Sale $48,753 +8.9%−33.4%−20.3%
August 19, 2019August 16, 2019 NKTR Sale $32,833 −2.8%−5.7%−11.0%
May 17, 2019May 16, 2019 NKTR Sale $60,481 −47.9%−35.4%−31.3%
February 21, 2019February 19, 2019 NKTR Sale $76,641 −18.9%−61.9%−70.7%
November 19, 2018November 16, 2018 NKTR Sale $153,612 +1.1%−67.1%−68.3%
May 18, 2018May 16, 2018 NKTR Sale $298,203 −32.4%−66.4%−69.7%
February 20, 2018February 16, 2018 NKTR Sale $211,082 −6.6%−59.0%−52.3%
August 18, 2017August 16, 2017 NKTR Sale $51,159 +146.2%+228.2%+189.9%
May 18, 2017May 16, 2017 NKTR Sale $51,827 −7.1%+323.6%+323.5%
February 17, 2017February 16, 2017 NKTR Sale $25,820 +42.1%+528.3%+524.1%
November 18, 2016November 16, 2016 NKTR Sale $27,725 −10.3%+249.7%+201.9%
August 17, 2016August 16, 2016 NKTR Sale $69,731 −21.6%−11.3%−4.2%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Thomsen Jillian B. traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.